NEW YORK (GenomeWeb News) – Gene Network Sciences will process clinical data from Biogen Idec to identify targets and biomarkers for inflammation, GNS said today.
 
GNS will use the data to develop a forward-simulation model that Biogen will then license.
 
GNS uses massively parallel supercomputers to search through “vast amounts of raw human biological data” for causes of disease and information about disease treatment, the company said.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.